Company Description
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections.
It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand.
The company is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 143 |
| CEO | Paula Ragan |
Contact Details
Address: 61 North Beacon Street, 4th Floor Boston, Massachusetts 02134 United States | |
| Phone | 857 529 8300 |
| Website | x4pharma.com |
Stock Details
| Ticker Symbol | XFOR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001501697 |
| CUSIP Number | 98420X103 |
| ISIN Number | US98420X1037 |
| Employer ID | 27-3181608 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paula Ragan Ph.D. | Chief Executive Officer, President and Director |
| Adam S. Mostafa | Chief Financial Officer, Treasurer and Corporate Secretary |
| Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Dr. Richard Peters M.D., Ph.D. | Chairman of the Board and Founder |
| Dr. Renato T. Skerlj Ph.D. | Founder |
| Dr. Keith T. Flaherty M.D. | Founder and Member of Corporate Advisory Board |
| Dr. Mary DiBiase Ph.D. | Chief Operating Officer |
| Dr. Arthur Taveras Ph.D. | Chief Scientific Officer |
| Natasha Thoren Esq. | Vice President, General Counsel and Compliance Officer |
| Dr. Robert David Arbeit | Senior Vice President of Clinical Development and Translational Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | 8-K | Current Report |
| Apr 18, 2025 | 8-K | Current Report |
| Mar 26, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 24, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 14, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 6, 2025 | 8-K | Current Report |
| Jan 31, 2025 | SCHEDULE 13G/A | Filing |